Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1635281 | 0.88 | L3MBTL1 (0.50) | L3MBTL1MAPTKMT2ATSHRKAT6A | |
| SCHEMBL1634828 | 0.86 | L3MBTL1 (0.53) | L3MBTL1MAPTKMT2ATSHRKAT6A | |
| SCHEMBL1634552 | 0.83 | L3MBTL1 (0.53) | L3MBTL1MAPTKMT2ATSHRKAT6A | |
| SCHEMBL1635482 | 0.82 | L3MBTL1 (0.48) | L3MBTL1PKMMAPTKMT2ATSHR | |
| SCHEMBL1634932 | 0.81 | NPC1 (0.49) | L3MBTL1MAPTKMT2ASMN1; SMN2GAA | |
| SCHEMBL1634310 | 0.80 | SMPD1 (0.39) | PKMMAPTSMN1; SMN2GAA | |
| SCHEMBL1635284 | 0.75 | SMPD1 (0.39) | KMT2ASMN1; SMN2 | |
| SCHEMBL1634642 | 0.74 | L3MBTL1 (0.55) | L3MBTL1MAPTKMT2ATSHRSMN1; SMN2 | |
| SCHEMBL1635864 | 0.74 | FOLH1 (0.43) | KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL1634641 | 0.72 | L3MBTL1 (0.56) | L3MBTL1MAPTKMT2ATSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932242-B2 | Anticancer agents; radiation and chemical resistance | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2011-04-26 | — | — | US | disclosed |
| US-20080058290-A1 | Substituted Phenoxy-and Phenylthio-Derivatives for Treating Proliferative Disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058290-A1 | Substituted Phenoxy-and Phenylthio-Derivatives for Treating Proliferative Disorders | PCNA, MKI67, TP53 | L3MBTL1 2021/4885PKM 1048/4885MAPT 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.